{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:10:52Z","timestamp":1784124652952,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015851","name":"OPKO Health, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) driven by dysregulated vitamin D metabolism. The serum 25-hydroxyvitamin D (25D) levels required for targeted intact parathyroid hormone (iPTH) reductions are poorly defined, and conventional sufficiency thresholds of 20 or 30 ng\/ml are inadequate. Exposure\u2013response (E\u2013R) modeling was used to define a 25D range associated with a 30% iPTH reduction during treatment with extended-release calcifediol (ERC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>E\u2013R relationships between 25D and iPTH were evaluated using pooled data from randomized clinical trials of ERC in participants with SHPT, CKD stage 3\u20134, and vitamin D insufficiency (VDI). Mixed-effects models characterized percent change in iPTH as a function of concurrent 25D. Mechanistic analyses evaluated associations between 25D, its key metabolites, and iPTH. Associations between achieved 25D and markers of mineral metabolism were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>E\u2013R modeling demonstrated a nonlinear relationship between 25D and iPTH reduction with a population-average of 84 ng\/ml associated with 30% iPTH reduction (ER30), ranging from 67 to 103 ng\/ml across the range of kidney function. Baseline body weight and sex significantly influenced achieved 25D concentrations. Higher achieved 25D was not associated with adverse changes in calcium, phosphorus, or fibroblast growth factor 23. Circulating 1,25-dihydroxyvitamin D was not independently associated with iPTH response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevation of 25D to 84 ng\/ml (range: 66.9\u2013102.6 ng\/ml) during ERC treatment was associated with a 30% iPTH reduction in participants with SHPT, CKD stage 3\u20134, and VDI. This range was unassociated with adverse changes in mineral metabolism.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag194","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:52:08Z","timestamp":1781092328000},"source":"Crossref","is-referenced-by-count":0,"title":["Extended-release calcifediol identifies a therapeutic vitamin D range in chronic kidney disease stages 3 and 4"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-3849","authenticated-orcid":false,"given":"John","family":"Choe","sequence":"first","affiliation":[{"name":"OPKO Health, Inc. , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Ashfaq","sequence":"additional","affiliation":[{"name":"OPKO Health, Inc. , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7877-6795","authenticated-orcid":false,"given":"Charles W","family":"Bishop","sequence":"additional","affiliation":[{"name":"OPKO Health, Inc. , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026071509380004000_bib1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"Lancet"},{"key":"2026071509380004000_bib2","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/13543784.2024.2369307","article-title":"Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs","volume":"33","author":"Magagnoli","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2026071509380004000_bib3","doi-asserted-by":"publisher","first-page":"i15","DOI":"10.1093\/ckj\/sfae423","article-title":"Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism","volume":"18","author":"Mazzaferro","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026071509380004000_bib4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.kint.2023.07.010","article-title":"Vitamin D supplementation in people with chronic kidney disease","volume":"104","author":"Vervloet","year":"2023","journal-title":"Kidney Int"},{"key":"2026071509380004000_bib5","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/S0021-9258(18)69191-4","article-title":"5\u2019-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3","volume":"263","author":"Okazaki","year":"1988","journal-title":"J Biol Chem"},{"key":"2026071509380004000_bib6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2026071509380004000_bib7","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/nu14153009","article-title":"Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future","volume":"14","author":"Brandenburg","year":"2022","journal-title":"Nutrients"},{"key":"2026071509380004000_bib8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/ckj\/sfab091","article-title":"Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis","volume":"14","author":"Cozzolino","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026071509380004000_bib9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"2026071509380004000_bib10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/j.ajkd.2024.03.025","article-title":"Vitamin D metabolites before and after kidney transplantation in patients who are anephric","volume":"84","author":"J\u00f8rgensen","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026071509380004000_bib11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/ki.1988.190","article-title":"Extra-renal production of calcitriol in chronic renal failure","volume":"34","author":"Dusso","year":"1988","journal-title":"Kidney Int"},{"key":"2026071509380004000_bib12","doi-asserted-by":"publisher","first-page":"57(1):109","DOI":"10.1159\/000546615","article-title":"Extended-release calcifediol normalized 1,25-dihydroxyvitamin D and prevented progression of secondary hyperparathyroidism in hemodialysis patients in a randomized clinical trial","author":"Bishop","year":"2026","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib13","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1210\/jc.87.6.2967","article-title":"25-Hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands","volume":"87","author":"Segersten","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071509380004000_bib14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.abb.2012.02.016","article-title":"Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase","volume":"523","author":"Adams","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"2026071509380004000_bib15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsbmb.2012.01.010","article-title":"Distribution and regulation of the 25-hydroxyvitamin D3 1\u03b1-hydroxylase in human parathyroid glands","volume":"130","author":"Ritter","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026071509380004000_bib16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib17","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.34067\/KID.0000000982","article-title":"Managing dysregulated vitamin D metabolism in CKD: time to update conventional wisdom?","volume":"6","author":"Bishop","year":"2025","journal-title":"Kidney360"},{"key":"2026071509380004000_bib18","doi-asserted-by":"publisher","first-page":"e111265","DOI":"10.1371\/journal.pone.0111265","article-title":"The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers","volume":"9","author":"Ekwaru","year":"2014","journal-title":"PLoS One"},{"key":"2026071509380004000_bib19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/ndt\/gfw080","article-title":"Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease","volume":"31","author":"Agarwal","year":"2016","journal-title":"Nephrol Dial Transpl"},{"key":"2026071509380004000_bib20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12882-018-1055-6","article-title":"High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy\u2014an observational cross-sectional study","volume":"19","author":"Dierkes","year":"2018","journal-title":"BMC Nephrol"},{"key":"2026071509380004000_bib21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000524289","article-title":"Extended-release calcifediol effectively raises serum total 25-hydroxyvitamin D even in overweight nondialysis chronic kidney disease patients with secondary hyperparathyroidism","volume":"53","author":"Bishop","year":"2022","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib22","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1007\/s00198-016-3574-y","article-title":"25-Hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese","volume":"27","author":"Camozzi","year":"2016","journal-title":"Osteoporos Int"},{"key":"2026071509380004000_bib23","doi-asserted-by":"publisher","first-page":"e10397","DOI":"10.1002\/jbm4.10397","article-title":"Obesity represses CYP2R1, the vitamin D 25-hydroxylase, in the liver and extrahepatic tissues","volume-title":"J Bone Min Res Plus","author":"Elkhwanky","year":"2020"},{"key":"2026071509380004000_bib24","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/jbmr.5650090818","article-title":"Profile of ligand specificity of the vitamin D binding protein for 1\u03b1,25-dihydroxyvitamin D3 and its analogs","volume":"9","author":"Bishop","year":"1994","journal-title":"J Bone Min Res"},{"key":"2026071509380004000_bib25","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00394-023-03103-1","article-title":"Calcifediol: a review of its pharmacological characteristics and clinical use in correcting vitamin D deficiency","volume":"62","author":"Jodar","year":"2023","journal-title":"Eur J Nutr"},{"key":"2026071509380004000_bib26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","article-title":"Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation","volume":"148","author":"Petkovich","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026071509380004000_bib27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000529523","article-title":"Evaluation of therapies for secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"9","author":"Strugnell","year":"2023","journal-title":"Kidney Dis"},{"key":"2026071509380004000_bib28","doi-asserted-by":"publisher","first-page":"Aug 27:1","DOI":"10.1159\/000541138","article-title":"Sustained reduction of elevated intact parathyroid hormone concentrations with extended-release calcifediol slows chronic kidney disease progression in secondary hyperparathyroidism patients","author":"Bishop","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1159\/000369939","article-title":"Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"40","author":"Sprague","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1159\/000518545","article-title":"Real-world assessment: clinical effectiveness and safety of extended-release calcifediol","volume":"52","author":"Fadda","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026071509380004000_bib32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071509380004000_bib33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ndt\/gfae293","article-title":"The role of nutritional vitamin D in chronic kidney disease\u2013mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation: a European consensus statement","volume":"40","author":"J\u00f8rgensen","year":"2025","journal-title":"Nephrol Dial Transpl"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag194\/68507019\/sfag194.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag194\/68507019\/sfag194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/7\/sfag194\/68507019\/sfag194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:38:07Z","timestamp":1784122687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag194\/8705450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag194","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,10]]},"article-number":"sfag194"}}